Momenta Pharmaceuticals, Inc. (
Q3 2011 Earnings Call
November 07, 2011 10:00 am ET
Beverly Holley - Director, IR
Craig Wheeler - President & CEO
Rick Shea - CFO
Ritu Baral - Canaccord
Eric Schmidt - Cowen and Company
Sapna Srivastava - Goldman Sachs
Joseph Schwartz - Leerink
Bret Holley - Oppenheimer Securities
Duane Nash - Wedbush Securities
Ami Fadia - UBS
Avik Roy - Monness, Crespi
Good day, ladies and gentlemen, and welcome to the Momenta Pharmaceuticals third quarter 2011 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to introduce your host for today, Ms. Beverly Holley, Director of Investor Relations. Ma’am, please go ahead.
Thank you and good morning. I want to welcome all of you to Momenta’s conference call to discuss financial results for the third quarter of 2011 and to provide a corporate update. With me on the call today with prepared remarks, Mr. Craig Wheeler, President and Chief Executive Officer, and Rick Shea, Chief Financial Officer. Following our remarks, we’ll open the call to questions.
Before we begin, I’d like to mention that our call today will contain forward-looking statements about management’s future expectations, beliefs, plans and prospects. These forward-looking statement including comments about our enoxaparin sodium injection commercial prospects and our generic competitors’ prospects for approval and commercialization; our generic Copaxone program, ANDA review and litigation expectations; and our other product development plans and expectations, including our future development, partnering and commercialization potential for our development programs.